For someone exploring GLP-1 treatment in Indonesia, three questions are more useful than a generic price list: Is the exact medicine registered for the relevant use? Who provides medical assessment? What will the complete course of care cost?
Local-language quick guide
Ringkasan Bahasa Indonesia: Sebelum mempertimbangkan layanan GLP-1 di Indonesia, periksa informasi registrasi obat melalui Cek BPOM, pastikan tenaga medis dan fasilitas berizin, serta mintalah rincian biaya dalam rupiah. Daftar ini tidak menjamin obat tertentu tersedia atau terdaftar.
The detailed guide below is currently in English. Other language editions require editorial review before publication.
Where to verify a GLP-1 medicine in Indonesia
Use Cek BPOM to check the product name, registration number (NIE), registrant and current status. A product listing is not, by itself, a recommendation for a particular patient.
Open the official Badan Pengawas Obat dan Makanan (BPOM) resource and keep the product name and registration details with the date checked. Search results can change, and a registration for one brand, indication or presentation should not be extended to another.
GLP-1 medicines are not a single interchangeable group. Semaglutide and tirzepatide have different receptor actions and can have different labels or permitted indications across markets. The WHO’s 2025 guideline discusses these therapies for adults with obesity as part of broader care, rather than a substitute for medical assessment.
Finding weight-management clinics
Our Indonesia clinic directory links to documented provider websites rather than asserting that every listed clinic offers a particular prescription. Sirka Metabolic Clinic and RS Pondok Indah are source-linked starting points. Confirm any GLP-1 evaluation, prescriber and medicine availability directly, rather than inferring them from an obesity-service page.
A useful first contact should establish clinician qualifications, referral requirements, relevant examinations, ongoing reviews, the exact prescribing and dispensing pathway, and how to handle adverse effects or treatment changes.
Understanding GLP-1 costs in IDR
Look beyond medicine quotes: request costs for clinician visits, lab tests, the dispensing channel and return appointments in Indonesian rupiah. Check whether the provider is a licensed medical establishment.
Ask for BPOM registration details where applicable, the name of the responsible clinician, and a written cost breakdown in IDR that distinguishes testing from medicines.
Use the GLP1Asia treatment cost calculator with quoted fees. It calculates a scenario from your entries; it is not a price database. You can also read how to compare treatment costs.
Which GLP-1 medicines should I compare?
Start with two research summaries: semaglutide in Asia and tirzepatide in Asia. They explain the medicine classes, common consultation questions and why brand registration must be checked country by country. The treatment comparison covers additional agents and research-stage compounds.
Frequently asked questions about GLP-1 in Indonesia
How do I verify a GLP-1 medicine in Indonesia?
Check the official register published by Badan Pengawas Obat dan Makanan (BPOM), using the exact brand, active ingredient or registration number. A generic website mention is not proof of a specific current registration.
How much does GLP-1 care cost in Indonesia?
It depends on the provider and what is included. Ask for itemised consultation, diagnostics, follow-up and any medicine cost in IDR; a screening package is not a medicine price.
Can I find GLP-1 clinics in Indonesia?
GLP1Asia lists source-linked obesity or weight-management service references. Confirm with each provider whether a qualified clinician currently offers GLP-1 evaluation and which medicines, if any, are available.
Are semaglutide and tirzepatide the same?
No. Semaglutide acts at the GLP-1 receptor; tirzepatide acts at GIP and GLP-1 receptors. Indications, products, clinical decisions and country-specific registration are not interchangeable.
Does a clinic listing mean GLP1Asia has verified a doctor or product?
No. Listing links show a source for an organisation or service; they are not an independent licence audit or proof of prescribing availability.
How often is information about Indonesia checked?
Automated checks may detect website changes, with regulatory sources checked when due and some directory and price sources scheduled weekly. A successful fetch is not proof that clinical information or current product status has been verified.
Primary sources and next checks
- Badan Pengawas Obat dan Makanan (BPOM) — official medicine or regulator information
- World Health Organization — 2025 GLP-1 obesity guideline
- MedlinePlus — semaglutide medicine information
- MedlinePlus — tirzepatide medicine information